Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts
FAL
0.375
97.4%
HLX
0.001
-50%
ATH
0.015
66.7%
TMK
0.002
-33.3%
GGE
0.003
50%
BMG
0.007
-30%
RMI
0.02
42.9%
ALR
0.003
-25%
CMB
0.3
39.5%
BLZ
0.003
-25%
MGU
0.008
33.3%
GTR
0.003
-25%
CMG
0.13
31.3%
PRS
0.018
-21.7%
BCA
0.235
30.6%
ADD
0.02
-20%
PGY
0.013
30%
VEN
0.004
-20%
GLA
0.009
28.6%
CLG
0.046
-19.3%
NPM
0.027
28.6%
G88
0.009
-18.2%
PH2
0.105
28%
CDE
0.023
-17.9%
SRL
1.345
27.5%
IPB
0.005
-16.7%
GBZ
0.019
26.7%
SER
0.005
-16.7%
FHS
0.005
25%
TX3DA
0.1
-16.7%
LKY
0.085
25%
IBX
0.016
-15.8%
EGR
0.32
23.1%
SCN
0.017
-15%
JGH
0.032
23.1%
VUL
3.48
-13%
NSB
0.16
23.1%
RON
0.135
-12.9%
ILU
4.89
22.9%
W2V
0.007
-12.5%
